Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Eiger Highlights Publication Of ILIAD Study Results Of Peginterferon Lambda In COVID-19 Published In Lancet Respiratory Medicine 2021


Benzinga | Feb 8, 2021 08:02AM EST

Eiger Highlights Publication Of ILIAD Study Results Of Peginterferon Lambda In COVID-19 Published In Lancet Respiratory Medicine 2021

PALO ALTO, Calif., Feb. 8, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced that final results from the Phase 2 ILIAD (Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19) study published in Lancet Respiratory Medicine.






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC